Novartis Ranks Fourth in Fortune’s “Change the World” List and Moves up in Dow Jones Sustainability Index
Novartis has again been recognized for its commitment to doing well by doing good in key global rankings.
September 11, 2017 /3BL Media/ - Novartis has again been recognized for its commitment to doing well by doing good in key global rankings.
Fortune’s “Change the World” list, published online on Thursday, September 7, placed Novartis in fourth place out of 50 companies listed. The list, now in its third year, recognizes companies that have a positive social impact through activities that are part of their core business strategy. This is the second time that Novartis is being recognized; the company was also listed in 2015 for its Healthy Family program in India (Arogya Parivar).
Novartis is “finding the right balance between a potent drug pipeline and people-friendly pricing,” writes Fortune.
Beyond the scientific breakthrough, Novartis is commended for its innovative approach to value-based pricing that focuses on the value medicines deliver with respect to clinical, patient, health system and societal outcomes.
Fortune also acknowledges Novartis innovative social business models, specifically Novartis Access, a program that offers treatments against chronic diseases to governments and public-sector customers in lower-income countries at a price of USD 1 per treatment per month, and the Healthy Family programs that serve rural populations in lower-income countries through a mix of health education, affordable healthcare products and capacity-building activities.
Also released on Thursday, Novartis ranked fourth in the 2017 Dow Jones Sustainability Index (DJSI) World (up from 7th in 2016), and re-entered the DJSI Europe Index for the first time in four years.
Novartis is rated as the industry leader in four categories: labor practices, materiality, climate strategy, and environmental reporting. The company also performed strongly versus the industry in new categories, including human rights and impact measurement and valuation.
The DJSI assessment has become the gold-standard for assessing the ESG (environmental, social and governance) performance of companies worldwide.
Learn more about Novartis’ corporate responsibility commitments and work to expand access to healthcare here on Novartis.com, https://www.novartis.com/about-us/corporate-responsibility
View Fortune’s “Change the World” list here, http://fortune.com/change-the-world/
